Durable, ongoing near-complete response to nivolimab + relatlimab in a 64-year-old with locally-advanced BCC after resistance to 26 weeks of nivolimab alone. Photo by: Evan Lipson, M.D. A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in treatment. Results from the phase 2 clinical trial (NCT03521830), presented Oct. 20 at the European Society

Findings from a recent phase II clinical trial show promising results for the immune checkpoint inhibitor nivolumab in the treatment of...

Findings from a study of patients with stage III melanoma treated with a combination of the immune checkpoint inhibitors relatlimab and...

Findings from a new study suggest that inhibiting both the LAG-3 and PD-1 immune checkpoints in patients with previously untreated...